Biocompatibles faces a long climb back to regain share values but may succeed in the longer term
This article was originally published in Clinica
Biocompatibles, the former high-flying UK biotechnology company whose share price is now trading at around one-tenth of its peak value, is unlikely to see much improvement in its stock market performance in the near future, say UK analysts.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.